Lapatinib and chronic renal insufficiency

Lapatinib e insufficienza renale cronica

Authors

  • Luca Moscetti Dipartimento di Oncologia-Ematologia, Azienda Ospedaliero-Universitaria di Modena, Modena (Italy)

DOI:

https://doi.org/10.19156/abtpn.2018.0031

Keywords:

Lapatinib, breast cancer, metastatic breast cancer, HER2

Abstract

Lapatinib is an intracellular tyrosine-kinase inhibitor of both EGFR (ErbB1) and HER2 (ErbB2) receptors, which is indicated in the treatment of metastatic disease pretreated with anti-HER2 therapies. We report the clinical case of a woman with chronic renal failure in dialysis affected by HER2-positive metastatic breast neoplasia and treated with lapatinib and letrozole (Oncology).

Downloads

Download data is not yet available.

Downloads

Published

2018-03-14

How to Cite

Moscetti, L. (2018). Lapatinib and chronic renal insufficiency: Lapatinib e insufficienza renale cronica. AboutOpen, 4(1), 5–7. https://doi.org/10.19156/abtpn.2018.0031

Issue

Vol. 4 No. 1 (2018): January - December 2018

Section

Case report

License

Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon. 

Metrics

Crossref
Scopus
Google Scholar
Europe PMC